CLINICAL_TRIALS ClinicalTrials.gov record update

Topoisomerase 2-Alpha (TOPO2A) Genomic Alterations and Immunohistochemical Expression as Well as Chromosome 17 Polysomy in Advanced or Recurrent Endometrial Carcinoma Treated With Anthracycline-Based Therapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01164735
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:17.624158+00:00
Published At: 2024-08-14T00:00:00+00:00
Record Updated At: 2024-08-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Uterine Corpus Carcinoma", "Stage III Uterine Corpus Cancer", "Stage IV Uterine Corpus Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-08-14"
protocolSection.identificationModule.nctId: "NCT01164735"
protocolSection.identificationModule.officialTitle: "Topoisomerase 2-Alpha (TOPO2A) Genomic Alterations and Immunohistochemical Expression as Well as Chromosome 17 Polysomy in Advanced or Recurrent Endometrial Carcinoma Treated With Anthracycline-Based Therapy"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.